Researchers at Queen’s University of Belfast and collaborators have developed a DNA vaccine against high-grade serous ovarian ...

Researchers from the Universitat de Barcelona and Oregon Health & Science University have developed a novel gene silencing ...

Biomea Fusion Inc. has released preclinical findings from a 28-day weight loss study in obese nonhuman primates evaluating ...

Researchers from Genentech Inc. have developed a novel single-domain antibody (VHH) targeting the IL-23 signaling pathway, which can be administered orally to effectively treat inflammatory bowel ...

Additional early-stage research and drug discovery news in brief, from: Arialys, Hamlet, Hoth, Neurizon, Telomir, Zetagen.

Diagonal Therapeutics Inc.’s DIAG-723 has been awarded orphan drug designation by the FDA for the treatment of hereditary hemorrhagic telangiectasia (HHT). Additionally, the EMA has provided a ...

Sudo Biosciences Ltd. has divulged non-receptor tyrosine-protein kinase TYK2 (JH2 domain) inhibitors reported to be useful for the treatment of rheumatoid arthritis, multiple sclerosis, psoriasis, ...

Evopoint Biosciences Co. Ltd. has disclosed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding moiety coupled to an Aurora kinase A (AURKA; ARK1)-targeting moiety ...

Synfini Inc. and O2nix Bio have established a strategic collaboration to co-discover and develop novel drug candidates targeting FTSJ1, a tRNA-modifying enzyme implicated in metastatic cancer cell ...

Actio Biosciences Inc. has synthesized potassium channel subfamily T member 1 (KCNT1) inhibitors reported to be useful for the treatment of Brugada’s syndrome, early infantile epileptic encephalopathy ...

Zhejiang Jingke Pharmaceuticals Co. Ltd. has identified mast/stem cell growth factor receptor kit (KIT; c-Kit; CD117) inhibitors reported to be useful for the treatment of cancer, neurodegeneration, ...

Sillajen Inc. has recently presented data regarding their threonine tyrosine kinase (TTK) and Polo-like kinase 1 (PLK1) dual inhibitor BAL-0891 as a therapeutic approach for acute myeloid leukemia ...